BiotechTube
VerAvanti

VerAvanti

San Diego, United States· Est.
veravanti.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $16.8M

Overview

VerAvanti is a private, pre-revenue medical device innovator founded in 2018 and based in San Diego. The company is developing a disruptive intravascular imaging platform using its patented Scanning Fiber Endoscope (SFE) technology, which offers forward-looking, real-time, full-color video from a 1mm catheter. This technology targets significant gaps in current side-view imaging (IVUS, OCT) and angiography, particularly for visualizing Chronic Total Occlusions (CTOs) and embolic sources. VerAvanti's device has the potential to improve procedural success rates, patient safety through a single-use design, and hospital operational efficiency.

Cardiovascular DiseaseNeurologyPeripheral Artery Disease

Technology Platform

Scanning Fiber Endoscope (SFE) using a Microelectromechanical System (MEMS) to scan a laser at the tip of a 1mm catheter, enabling forward-looking, real-time, full-color (1080p) video imaging inside blood vessels and small body spaces.

Funding History

2
Total raised:$16.8M
Series A$15M
Seed$1.8M

Opportunities

The major opportunity lies in addressing the large, underserved patient populations with Chronic Total Occlusions (CTOs) and Embolic Strokes of Undetermined Source (ESUS), where current imaging technologies are inadequate.
Successfully commercializing the SFE could establish a new standard of care in forward-looking intravascular visualization, creating a premium segment in the growing intravascular imaging market.

Risk Factors

Key risks include the technical challenge of transitioning an advanced prototype into a robust, manufacturable medical device, and the regulatory hurdle of obtaining FDA clearance.
Furthermore, convincing clinicians to adopt a novel imaging modality and securing adequate reimbursement from payers present significant commercial and adoption risks.

Competitive Landscape

VerAvanti's primary competitors are established intravascular imaging modalities: side-viewing Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) from giants like Philips, Boston Scientific, and Abbott, as well as angiography. The SFE's forward-looking, full-color capability is a clear differentiator, positioning it as a complementary or potentially superior tool for specific applications like navigating CTOs, rather than a direct replacement for cross-sectional imaging.

More companies in Diagnostics & Precision Medicine →More companies in United States →